Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02154776

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. — LeeBLet  

Advanced or Metastatic Breast Cancer Clinical Trial

Official title:
A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.

Clinical Trial Summary

This is a multi-center, open-label, non-randomized, phase I study

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02154776
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 1
Start date June 27, 2014
Completion date October 26, 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase 1/Phase 2
Recruiting NCT05187832 - A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer Phase 1
Completed NCT01625286 - Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Phase 1/Phase 2
Terminated NCT05932667 - Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer Phase 2
Completed NCT05519059 - Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer Phase 1
Recruiting NCT04742153 - A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) Phase 2
Not yet recruiting NCT06201234 - Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Phase 2
Active, not recruiting NCT04494425 - Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Phase 3
Completed NCT03767335 - MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer Phase 1
Recruiting NCT06105632 - A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment Phase 3
Completed NCT01676753 - Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Phase 1
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1